

Table SI. Characteristics and response to antibiotics of patients diagnosed with primary cutaneous marginal zone lymphoma (PCMZL) presented in published articles

Year	Study (2-8)	Geographical area	N	Age, years/ Sex	Sero- logy	Culture	PCR DNA	IHC	Steiner stain	Antibiotics	Dose	Response to antibiotics
1997	Kutting et al.	Austria	1	28/M	Pos	Pos	Pos	ND	ND	Intravenous ceftriaxone and oral doxycycline	2 g QD for 2 weeks, 100 mg BID for 3 weeks	CR
2000	Roggero et al.	Switzerland	1	70/M	Pos	Neg	Pos	ND	ND	Intravenous ceftriaxone	2 g QD for 2 weeks	CR
2000	Goodlad et al.	England	1	57/M	ND	ND	Pos	ND	ND	Oral penicillin	NA	PD
2003	de la Fouchardiere et al.	France	1	NA	NA	NA	Pos	ND	ND	Yes	NA	CR
2005	Schreuder et al.	Netherlands	2	46/M 63/F	Pos Pos	ND ND	ND ND	ND ND	ND ND	Yes Yes	NA NA	NR NR
2007	Monari et al.	Italy	1	68/M	Neg	ND	Pos	ND	ND	Oral doxycycline	100 mg BID for 4 weeks	NR
2008	Golling et al.	Switzerland	11		NA	ND	NA	ND	ND	Oral doxycycline	100 mg BID for 3 weeks	PR 3/11 CR 0/11
2009	Sharon et al.	America	2	12/M 17/M	Neg Neg	ND ND	ND ND	ND ND	Neg ND	Oral doxycycline Oral tetracycline	100 mg BID for several months 500 mg BID	PD SD
2010	Breton et al.	France	1	70/F	Neg	ND	ND	ND	ND	Amoxicillin	3 weeks	NR
2010	Yildirim et al.	Turkey	1	51/M	Neg	ND	ND	ND	ND	Yes	NA	NR
2011	Aberer et al.	Austria	1	88/F	Pos	ND	Pos	ND	ND	Intravenous ceftriaxone	2 g QD for 3 weeks	PR
2013	Ghatalia et al.	America	1	15/M	Neg	ND	Neg	Pos	ND	Oral doxycycline	100 mg BID for 1 month	NR
2014	Kempf et al.	Switzerland	1	18/M	Neg	ND	Neg	ND	ND	Oral doxycycline	100 mg BID for 2 weeks	PR
2016	Bonin et al.	Italy	4	62/M 42/F 35/M 36/M	Pos Neg Neg Pos	ND ND ND ND	Pos Pos Pos Pos	ND ND ND ND	ND ND ND ND	Oral doxycycline Oral doxycycline Oral doxycycline Oral doxycycline	100 mg BID for 20 days 100 mg BID for 20 days 100 mg BID for 20 days 100 mg BID for 20 days	CR CR CR CR
2020	Jothishankar et al.	America	1	14/M	Neg	ND	ND	ND	ND	Oral doxycycline	100 mg BID for 1 month	NR

N; number; PCR; polymerase chain reaction; M; male; F; female; IHC; immunohistochemistry; Pos; positive; Neg; negative; ND; not done; NA; not available; NR; no response; PR; partial response; CR; complete response; PD; progression disease; SD; stable disease.